Elite Pharmaceuticals Inc (QB) (ELTP) News

Interesting MM activity today. The MM ARCA, an electronically traded NYSE market maker is listed on the offer at .458 for 7k on IH list. They are not listed on the SCHAB MM list as they usually not active on the OTC exchange. When they appear it usually presages some volatility on volume. We shall see.

Monday morning Kool aide drinkers are out in full fantasy land i see. Sub 12 is coming. Bridges are being produced.

He's making us all into millionaires and multimillionaires .
Hes busy selling Elite for us..
Listen to last CC for details.

GLTY

Toppin' off till sale finalized

Quarter/YEAR ends on the 31st

We are in the Quiet period.
Co. is for sale.

Listen to last CC

GLTY

With the introduction of Lisdex to the drug portfolio, Elite now has a relatively expensive product for a generic with a large profit margin. The final quarter numbers, which end this week, will probably reflect a nice profit to add to the PE multiple. An increasing forward looking PE ratio should be attractive for a potential suitor. I expect a news event soon to cause volume and liquidity to resume. I continue to have a Let It Ride mentality.

I really think MIKAH is an issue with elite hiring investment bankers. I think he’s concerned with the questions that will be asked. Just my opinion.

We can debate the strategy all day. We've now pushed long-time allies to the acquaintance pool. I sit down with CFOs and CEOs on a weekly basis. You can read all you want in the press, it's absolute frustration and chaos running companies due to all this uncertainty caused by tariffs for global organizations. The pressure will continue to build. 

Some Trump tariffs are bargaining chips that are created to help the trading balance between countries.

The Tariffs on Meds has a different purpose - and it is to bring back factories to the USA and grow the US economy. This one is likely to stay.

More pushing out to the future. Nasrat has been ceo since 2013. How about he does something today that’s meaningful. Tired of him being the only one making money

https://www.cnbc.com/2025/03/23/stock-market-today-live-updates-.html
Tariffs getting pulled back took a couple of weeks less than I had expected. Administration is starting to realize how idiotic their plan was to blanket the world with tariffs. The chaos and uncertainty they caused among small and large businesses was beyond alarming.

Another day with no news and investors looking forward to tomorrow, next week, next month and even next year. Who is making money - Nasrat. Million dollar salary, home and car allowance , MIKAH , MIKAH and more MIKAH, loans that he’s charging 10% on and oh yeah, MIKAH. I don’t blame the guy, life is good when you’re the ceo of two of your own companies. Oh wait, elite is a Public company Sell the damn thing.

Just my pissed off opinion

He showed his hand by saying he’s 100% in this stock. Thats all I needed to hear!

Was this a post to payroll?

---------------
Message in reply to:
c*cksucker555 hasn't posted in over a month.

Thanks.

c*cksucker555 hasn't posted in over a month.

Thanks.

November 17, 2025 - This is the day of the conference call in which Elite will have a FULL quarter of sales for EVERY drug they have. I'm expecting $50+ million in revenue.

Anyone up for providing their, "Estimates" as to the 1st day Elite breaks the "One Buck Barrier"
: Any time at or above $1.00/share
-Clearleather: June 6, 2025

Anyone up for providing their, "Estimates" as to the 1st day Elite breaks the "One Buck Barrier" 
: Any time at or above $1.00/share 
-Clearleather: June 6, 2025

jour_trader is on record stating he's AFRAID to make a prediction.

would be nice if we could get back to some serious pricing discussions.

"$2.00 or no deal"

nobody takes the $7 valuation seriously. i don't know if anyone takes $3.50 seriously. would be nice if we could get back to some serious pricing discussions. i know it's a mostly impossible thing though.

nobody takes the $7 valuation seriously. i don't know if anyone takes $3.50 seriously. would be nice if we could get back to some serious pricing discussions. i know it's a mostly impossible thing though.

Hey $7.00, Using this Valuation method, is $7 w

Thanks for your quick response and it is appreciated.

Hi Hyder

I did not use this valuation method for the $7.

On top off any valuations we come up with, there are the 25% tariffs kicking in on April 2 nd. It will increase our price because of the 90k sqft facility approved by the fda and dea for tablets and capsules.

Hey $7.00, Using this Valuation method, is $7 what you arrive at and so is your ID?

All the proceeds of the gains from your 5k CC loan going under Henry’s bridge. lol

😂😂😂

WeeZuhl ALREADY has a lawyer lined up for us just in case.

We'll see how things play out over the next 6 months.

If needed, WeeZuhl will initiate the lawsuit.

Once initiated, WeeZuhl and the law firm will update Elite shareholders on the next steps in the process.

Can we file a shareholder lawsuit? Is it time to consider suing him and the board ? Just asking and just my opinion

https://contracts.justia.com/categories/mergers-and-acquisitions/elite-pharmaceuticals-inc-1799/

This maybe from 2012 ?

The big red X’s are so scary. Seems you are getting nervous

Nasrat, our genius CEO understands that the faithful investors have waited long enough to collect the fruits of their investment.

He also KNOWS how the valuation is performed:

Valuing a generic pharmaceutical company with a long history, extensive R&D, patents, a diverse product line, in-house salesforce, distribution, and a pipeline involves specialized approaches. Here's an overview of the valuation process and key calculation parameters:

---

### **Valuation Methods**

1. **Discounted Cash Flow (DCF) Analysis**:
- Projects future cash flows from existing products and pipeline drugs, discounted to present value.
- Accounts for R&D costs, manufacturing, and distribution expenses.
- Suitable for companies with established revenue streams.

2. **Comparable Company Analysis (CCA)**:
- Benchmarks the company against similar firms using trading multiples (e.g., EV/EBITDA, Price-to-Earnings) or transaction multiples from M&A deals.
- Useful for assessing market positioning and competitive dynamics.

3. **Risk-Adjusted Net Present Value (rNPV)**:
- Incorporates probabilities of success for pipeline drugs at various development stages (e.g., preclinical, Phase I-III, FDA approval).
- Adjusts cash flow projections based on clinical trial risks and regulatory hurdles.

4. **Sum-of-the-Parts (SOTP) Valuation**:
- Separately values each business segment (e.g., marketed products, pipeline, salesforce, distribution network) and aggregates them.
- Ideal for companies with diverse operations.

5. **Real Options Valuation**:
- Models flexibility in decision-making based on R&D outcomes and market conditions.
- Reflects the dynamic nature of pharmaceutical innovation.

---

### **Key Calculation Parameters**

1. **Revenue Drivers**:
- Sales from existing products.
- Market share and pricing power.
- Revenue growth from new product launches.

2. **Pipeline Evaluation**:
- Number and stage of pipeline drugs.
- Probability of success at each development stage.
- Potential market size and competition for pipeline drugs.

3. **R&D Investments**:
- Annual R&D expenditure.
- Efficiency of R&D in delivering successful products.

4. **Patent Portfolio**:
- Duration of patent protection for key products.
- Impact of patent expirations on revenue.

5. **Salesforce and Distribution**:
- Efficiency and reach of in-house salesforce.
- Costs and scalability of distribution networks.

6. **Regulatory Milestones**:
- FDA approvals and orphan drug designations.
- Compliance with international regulations.

7. **Market Dynamics**:
- Competitive landscape and pricing pressures.
- Trends in generic drug adoption and healthcare policies.

8. **Financial Metrics**:
- EBITDA margins, operating costs, and net income.
- Debt levels and cost of capital.

9. **Macroeconomic Factors**:
- Interest rates, inflation, and currency fluctuations.
- Global healthcare spending trends.

---

These methods and parameters provide a comprehensive framework for valuing a generic pharmaceutical company. Let me know if you'd like to explore any specific aspect further!

NasRAT would have to be the DUMBEST CEO on the PLANET if he tried to sell Elite right now or ANY time soon.

❌️ Still on the OTC
❌️ All the BE studies failed last year
❌️ Generic OxyContin uncertainty
❌️ Vyvanse JUST launched
❌️ Mikah owns half the Adderall profits
❌️ NasRAT hasn't exercised his warrants which is KILLING the income statement.

Kool aide drinkers need a new flavor. How about the new mix berry. Loaded with antioxidants and vitamins. Sub 12 cents is coming. Are you prepared? I got bridges on back order. Who wants that sub 12 cents flavor?

He’s suing cause he sold way to early and made Million$

...and how bout those numbers!

The share price has been going down since October 2024, slowly but surely so it's not Nasrat fault, it was a setup, I would bet money that Zacks had a hand in this situation. But the erosion does do major damages because no one knows when this will stop. Shaking out the weak hands could be just the beginning. What about the people that hold 1-3 million shares, over 500k easily been wipe out.
Percocet on Monday would be nice but is it another setup that brings the stock further down into the low .40's

Percocet on Monday?? 🐂🤑🤑🤑🤑🤑

You must have missed the last and best CC ever.

You should have not sold me your shares.
Sellers have failed.
ELTP

Thanks sharkey!!

Buyout now!

Not in 2026. Not in 2027. NOW!!! With a five years revenue projection

Ole snippy still here after selling not believing and then buying in the 50’s! Snippy you the best!!! ELTP$$$$$$$

Not bad enough for yall to sell and move on though.
Talk is cheap. IMO, if that sentiment was truly believed by those expressing it, they wouldn't still be invested in ELTP and wouldn't still be posting on this board.

Agreed!

Hey genius. A question isn't an opinion. Your lack of intelligence is showing.

Very good read sharkey1, ELTP$$$$$$$

Even the big boys are now looking for new local digs, on shore.

J&j is on the prowl , looking for Two new production plants.

https://finance.yahoo.com/news/j-j-boosts-us-operations-182247160.html

Destination unknown, Bet they looked at Elite.

Kool aide is bitter? Don't worry, its about to get more bitter. No worries I have bridges to sell you all. OTC fantasy world is harsh. Make up pipe dream stories, sell them to a bunch of desperate folks and then they hold on forever and ever. All while a few unload and laugh all the way to the bank. Its OTC fantasy world and happens all the time. Red flags are flying and waving like crazy. Sub 12 is here before you can blink. What bridge to do you like?

On this board if you are stupeed and you don’t know how to spell you can write any phucking information you want. Look at how the phucking king goes unpunished

Why can’t Nasrat simply issue a press release saying - we are in the process of hiring a bank to evaluate our strategic options to increase shareholder value. What’s the issue in doing this ?

Nasrat has failed us so we should focus on the company and less on others. Thanks.

Just my opinion.

Can we file a shareholder lawsuit? Is it time to consider suing him and the board ? Just asking and just my opinion

My opinion , he doesn’t give a nas rats ass about us. It’s all about Nasrat and family

Looks like the same group of people...

Purdue Pharma L.P. et al v. Accord Healthcare Inc.

https://www.pacermonitor.com/case/53616923/Purdue_Pharma_LP_et_al_v_Accord_Healthcare_Inc_et_al

Were any of Elite's lawyers involved in the Purdue/Accord trials. ??